Accuray Valuation Multiples

Accuray Overview

About Accuray

Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.

Founded

1990

HQ

Employees

990

Website

accuray.com

Sectors

Medical DevicesDeepTechHealthTech

Financials (LTM)

Revenue: $448M

EBITDA: $24M

EV

$198M

Valuation Multiples

Multiples.vc

Start free trial

Accuray Financials

Accuray reported last 12-month revenue of $448M and EBITDA of $24M.

In the same LTM period, Accuray generated $129M in gross profit, $24M in EBITDA, and had net loss of ($24M).

Accuray P&L

In the most recent fiscal year, Accuray reported revenue of $459M and EBITDA of $28M.

Accuray expects next 12-month revenue of XXX and NTM EBITDA of XXX

Accuray Stock Performance

Accuray has current market cap of $66M, and enterprise value of $198M.

Accuray's stock price is $0.55.

Accuray Valuation Multiples

Accuray trades at 0.4x EV/Revenue multiple, and 8.1x EV/EBITDA.

Accuray Financial Valuation Multiples

As of March 13, 2026, Accuray has market cap of $66M and EV of $198M.

Equity research analysts estimate Accuray's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Accuray has a P/E ratio of (2.7x).

Accuray Margins & Growth Rates

Accuray's revenue in the last 12 month grew by 2%.

Accuray's revenue per employee in the last FY averaged $0.5M.

Accuray's rule of 40 is 8% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Accuray's rule of X is 11% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Accuray Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Accuray M&A Activity

Accuray acquired XXX companies to date.

Last acquisition by Accuray was on XXXXXXXX, XXXXX. Accuray acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Accuray Investment Activity

Accuray invested in XXX companies to date.

Accuray made its latest investment on XXXXXXXX, XXXXX. Accuray invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).